An observational study in Papillary Thyroid Carcinoma and Thyroid Cancer, sponsored by Sohag University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Sohag University · Observational
The aim of this study is to evaluate the clinicopathological pattern and surgical outcome of papillary thyroid carcinoma (PTC) at Sohag University Hospitals. This will help improve local risk stratification, optimize surgical decision-making, and guide future management strategies for patients with PTC in this region.
Papillary thyroid carcinoma (PTC) is the most common histological subtype of thyroid cancer, representing about 80-85% of cases. This study is a case-series study with both retrospective (June 2023 - June 2026) and prospective (June 2026 - March 2027) components, conducted at the Department of General Surgery, Sohag University Hospitals.
All patients diagnosed with papillary thyroid carcinoma and managed at Sohag University Hospitals during the study period will be included. Data collection includes baseline demographic and clinical features, preoperative laboratory tests (thyroid function tests and serum calcium), neck ultrasonography findings (ACR TI-RADS category, nodule size, and lymph node assessment), fine-needle aspiration cytology (Bethesda System), surgical intervention types (hemithyroidectomy, total thyroidectomy, and neck dissection), final histopathological characteristics (tumor size, multifocality, lymphovascular invasion, extrathyroidal extension, and nodal status), and early postoperative complications (hypocalcemia, recurrent laryngeal nerve palsy, hematoma, seroma, and wound sepsis).
186 studies on the registry are indexed under Thyroid Cancer, Papillary; 51 are open to participants now.
This study's planned enrollment of 30 is below the median of 200 across 66 observational studies indexed under Thyroid Cancer, Papillary.
Browse Thyroid Cancer, Papillary studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with papillary thyroid carcinoma (PTC) who are admitted and managed at the Department of General Surgery, Sohag University Hospitals, serving as a tertiary care center in Upper Egypt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients diagnosed with papillary thyroid carcinoma (and its variants) managed at Sohag University Hospitals during the study period (June 2023 to March 2027).
Prevalence of Extrathyroidal Extension in Papillary Thyroid Carcinoma
Percentage of participants with histologically confirmed extrathyroidal extension.
Time frame: 9 months
Incidence of Early Postoperative Surgical Complications
Percentage of participants experiencing early postoperative complications including hypocalcemia, recurrent laryngeal nerve palsy, hematoma, seroma, or wound sepsis.
Time frame: 9 months
Incidence of Multifocal Papillary Thyroid Carcinoma
Percentage of participants found to have multifocal tumors on final histopathological examination.
Time frame: 9 months
Rate of Cervical Lymph Node Metastasis
Percentage of participants with histopathologically confirmed cervical lymph node metastasis.
Time frame: 9 months
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Mar 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.